OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Organization: Emory University

13 Projects | 10 Researchers | $3,287,561 Invested

2021

Emory University

Felicia Goldstein

Diagnostics Accelerator Speech & Language Consortium: Harmonized Repository for the Exploration of Speech and Language Biomarkers for Neurodegenerative Disease

  • Funding Amount: $559,959
  • Organization Type: Academic/Nonprofit
  • Program: Biomarkers
  • Status: Active

2017

Emory University

Thomas Kukar, PhD

Rescue of lysosomal dysfunction, neuroinflammation, and neurodegeneration by lysosomal GRN-2 in a mouse model of PGRN deficiency and Frontotemporal Dementia

  • Funding Amount: $150,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Proteostasis
  • Status: Closed

2016

Emory University

Thota Ganesh, PhD

EP2 antagonists for the suppression of inflamnation and neuropathology in Alzheimer's model - Year 2 [Add-On Funding]

  • Funding Amount: $77,618
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Neuroinflammation
  • Status: Closed

2015

Emory University

Ihab Hajjar, MD, MS

Effect of candesartan on prodromal Alzheimer's Disease and its related biomarkers

  • Funding Amount: $944,115
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: Vascular
  • Status: Closed

2014

Emory University

Thota Ganesh, PhD

EP2 antagonists for the suppression of inflammation and neuropathology in Alzheimer's model- Year 2

  • Funding Amount: $136,082
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Neuroinflammation
  • Status: Closed

2013

Emory University

Keqiang Ye, PhD

TrkB Agonist Drug Development for Treating Alzheimer's Disease

  • Funding Amount: $200,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

2013

Emory University

Thota Ganesh, PhD

EP2 antagonists for the suppression of inflammation and neuropathology in Alzheimer's model

  • Funding Amount: $101,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

2013

Emory University

Malu Tansey, PhD

Modulation of peripheral inflammation and immune cell traffic in AD by XPro1595

  • Funding Amount: $100,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

2012

Emory University

Allan Levey, MD, PhD

A phase IIa, double-blind, placebo-controlled, biomarker study of atomoxetine in subjects with mild cognitive impairment

  • Funding Amount: $447,900
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: Synaptic Activity and Neurotransmitters
  • Status: Closed

2011

Emory University

Allan Levey, MD, PhD

A phase IIa, double-blind, placebo-controlled, biomarker study of atomoxetine in subjects with mild cognitive impairment

  • Funding Amount: $280,000
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: Synaptic Activity and Neurotransmitters
  • Status: Closed
View More